Benitec Biopharma Inc.
About Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2021
- $59.0K
- Net income
- -$37.9M
- Total assets
- $99.6M
- Market cap
- $362.4M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $41.8M
- Operating income
- -$41.8M
- Net income
- -$37.9M
- EPS (basic)
- $-1.05
- EPS (diluted)
- $-1.05
Balance sheet
- Total assets
- $99.6M
- Current assets
- $98.5M
- Total liabilities
- $2.3M
- Current liabilities
- $1.8M
- Shareholders’ equity
- $97.3M
Cash flow
- Operating cash flow
- -$23.6M
- Investing cash flow
- -$18.0K
- Financing cash flow
- $70.5M
- Net cash flow
- $46.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $362.4M
- EPS (diluted)
- $-1.05
- Shares outstanding
- 34.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 11, 2012
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $37.9M in FY2021.
- Trading 37% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Benitec Biopharma Inc..
Write a review
News about Benitec Biopharma Inc.
News & sentiment via Polygon.io
